

## REMARKS

The claims have been amended to focus on the advantages of the invention. Support for new claim 71 is found on page 7, lines 21-27, page 8, lines 19-21 (for the definition of ligand) and on page 6, lines 1-5 and on page 12, beginning at line 12 (for fluorocarbon based emulsions) and throughout the specification. Support for the dependent claims 72 and 73 is found on page 14, at line 25, *et seq.* Support for claim 74 is found on page 6, lines 1-6 (with regard to surface contact). Support for the remaining dependent claims is found in claims 38-53 as originally filed. No new matter has been added and entry of the amendment is respectfully requested.

The claims as now presented reflect the improved ability of the invention methods to deliver drugs by virtue of the prolonged contact between the lipid/surfactant layer of the nanoparticles in the emulsion containing the drug and the hydrophobic cell surface. By virtue of the targeting ligand, which binds to a molecule on or in tissue or organ, the two hydrophobic surfaces remain in contact and are thus able to mediate the delivery of the drug.

Examination on the merits is now requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket No. 532512000401.

Respectfully submitted,

Dated: September 4, 2003

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive, Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125